Circulating Prostate Cancer Progenitor Cell Assay Development

Award Information
Agency:
Department of Defense
Amount:
$747,553.00
Program:
STTR
Contract:
W81XWH-08-C-0099
Solitcitation Year:
2008
Solicitation Number:
2008.A
Branch:
Army
Award Year:
2011
Phase:
Phase II
Agency Tracking Number:
A2-4144
Solicitation Topic Code:
A08-T041
Small Business Information
AndroBioSys, Inc.
73 High Street, Buffalo, NY, 14203-1149
Hubzone Owned:
Y
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
193493157
Principal Investigator
 Michael Zwick
 CEO
 (716) 860-7920
 mzwick@androbiosys.com
Business Contact
 Michael Zwick
Title: CEO
Phone: (716) 860-7920
Email: mzwick@androbiosys.com
Research Institution
 Roswell Park Cancer Institute
 John T Blandino
 Elm and Carlton Streets
Buffalo, NY, 14263-
 (716) 845-2312
 Domestic nonprofit research organization
Abstract
The technical objectives of this Phase II project are to identify unique biomarkers and produce molecular, antibody and peptide reagents that are specific for human prostate cancer progenitor stem cells. We propose to utilize the information from the Phase I award and subsequent research to develop assay reagents that would be used to develop a blood-based assay specific for circulating prostate cancer stem cells. This assay should prove to be an informative prognostic tool for predicting aggressiveness and metastatic potential of prostate cancer.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government